Overview

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

Status:
Completed

Trial end date:
2019-06-10

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Bendamustine Hydrochloride
Idelalisib
Rituximab